^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

EVT801

i
Associations
Company:
Evotec, Kazia
Drug class:
VEGFR-3 inhibitor
Associations
6ms
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours (clinicaltrials.gov)
P1, N=32, Active, not recruiting, Kazia Therapeutics Limited | Recruiting --> Active, not recruiting | N=60 --> 32
Enrollment closed • Enrollment change • Metastases
|
FLT4 (Fms-related tyrosine kinase 4)
|
EVT801
over1year
VEGFR-3 expression profiling by histology and mRNA signature to classify patient population for the selective VEGFR-3 inhibitor EVT801 (ESMO 2023)
This enables us to select indications that might benefit from EVT801 as a monotherapy (e.g., clear cell renal cell carcinoma and soft tissue sarcomas) or in combination with standard of care. Accordingly, VEGFR-3 expression is retrospectively quantified during the EVT801 phase 1 clinical trial and may be used to stratify patients in the future.
Clinical
|
CD34 (CD34 molecule) • FLT4 (Fms-related tyrosine kinase 4)
|
EVT801
almost2years
VEGFR-3 expression profiling by histology to classify patient population for the selective VEGFR-3 inhbitor EVT801 (AACR 2023)
This held true even in patients treated with sunitinib, positioning EVT801 as a potential treatment option after failure of such multi tyrosine kinase inhibitors. We were able to quantify VEGFR-3 expression in the kidney and soft tissue sarcoma cohorts plus several others, such as hepatocarcinoma and non-small cell lung cancer. This enables us selecting indications that might benefit from EVT801 as a monotherapy (e.g., clear cell renal cell carcinoma and soft tissue sarcomas) or in combination with standard of care. Accordingly, VEGFR-3 expression is retrospectively quantified during EVT801 clinical trial phase 1 trial and may be used to stratify patients in the future.
Clinical
|
CD34 (CD34 molecule) • FLT4 (Fms-related tyrosine kinase 4)
|
sunitinib • EVT801
almost3years
EVT801, a novel selective VEGFR-3 inhibitor targeting tumor angiogenesis, started enrollment for its phase I first-in-human study (AACR 2022)
A potential third stage, consisting of a multiple ascending dose evaluation of the combination of EVT801 with immuno-oncology drugs, may be added to the ongoing trial, pending further technical discussions with physicians and regulators. In addition to conventional measures of safety, tolerability, efficacy, and pharmacokinetics, the phase I study will employ a rich suite of histological, immunological, and radiological biomarkers to provide early insights into the activity of EVT801.
P1 data • IO biomarker
|
FLT4 (Fms-related tyrosine kinase 4)
|
EVT801
3years
Clinical • New P1 trial
|
FLT4 (Fms-related tyrosine kinase 4)
|
EVT801